Search the Newsreel

CareDx, Inc. 2Q 2026: Revenue $131.95M, EPS $2.07— 10-Q Summary

CareDx, Inc. (CDNA) reported strong second-quarter 2026 results with revenue of $131.95 million and diluted EPS of $2.07. This performance was significantly boosted by higher testing services volume, prior-period collections, and a one-time gain of approximately $113 million from the sale of its lab …

CareDx Number of Employees 2026 | Employee Count & Headcount Data

CareDx, Inc. (CDNA) had approximately 805 total employees worldwide as of March 2026, marking a 14.9% growth from 700 employees in 2023. The company is actively hiring, with 92 active job postings in 2026, though this represents a 28.0% decline from 2025. CareDx's workforce …

Earnings call transcript: CareDx beats Q2 2026 estimates and lifts outlook

CareDx, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CDNA) 2026-07-30

CareDx, Inc. (CDNA) reported impressive Q2 2026 earnings, significantly beating EPS and revenue expectations. The company saw a 59.5% beat on EPS with $0.37 against an estimated $0.23, and revenue reached $132 million, surpassing the $114 million estimate by 15.7%. This strong performance was …

CareDx (NASDAQ: CDNA) swings to profit, sells lab products unit and buys Naveris

CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates

CDNA|CareDx Inc|Price:36.380|Chg%:-0.760

This article provides a detailed company profile for CareDx Inc (CDNA), a precision medicine solutions company specializing in healthcare solutions for transplant patients. It outlines their business scope, including various testing services and digital solutions, and provides key financial data, market performance metrics, and …

CareDx Inc (CDNA) Earnings Date & Reports & Earnings News

CareDx Inc (CDNA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend history and stock splits for CareDx Inc (CDNA). It notes that the company has not distributed any dividends over the past five years. The page also presents current stock pricing, market capitalization, and links to various financial …

CareDx Inc (CDNA) Institutional Confidence

CareDx Inc (CDNA) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.54%, despite an 11.87% decrease quarter-over-quarter. Ron Baron is the largest institutional shareholder, holding 2.61 million shares, which …

CareDx (CDNA) Expected to Post Quarterly Earnings on Thursday

CareDx (CDNA) Earnings Expected to Grow: Should You Buy?

Is CareDx (CDNA) Fully Valued After Its Medicare Coverage Win?

CareDx (CDNA) is in focus after Medicare finalized coverage for its molecular transplant surveillance tests, leading to a significant recent surge in its stock price. While analysts and one valuation model view the stock as overvalued at $38.37 against a fair value of $27.80, …

This company is letting a virus guide its new focus on cancer testing

CareDx Inc. is changing its strategic direction to focus on cancer testing, a move influenced by a virus. CEO John Hanna emphasizes the importance of being a market leader in their chosen fields. This new focus is highlighted by their significant $260 million acquisition …

CareDx Inc (CDNA) Shares Fall 3.4% -- GF Value Says Still Overva

CareDx Inc (CDNA) shares dropped 3.4% to $38.37, yet its GF Value™ indicates the stock is significantly overvalued by 79.8%. Despite a GF Score™ of 66/100 suggesting above-average long-term potential, its valuation rank is low (1/10) and insiders have sold $8.3 million worth of …

CareDx (CDNA) Q1 2026 earnings summary

CareDx reported strong Q1 2026 results with a 39% year-over-year revenue increase to $118 million and a net income of $3 million. The company strategically divested its Lab Products business for $170 million and acquired Naveris/Navoris to enhance its focus on precision medicine and …

CareDx (CDNA) Proxy filing Summary

CareDx (CDNA) has released a proxy filing summary detailing voting matters and executive compensation. Stockholders are asked to approve the compensation of named executive officers for 2025, which includes a cash bonus program based on Revenue, Adjusted EBITDA, and Cash. The summary also clarifies …

CareDx (CDNA) Is Up 39.4% After Final Medicare Coverage Clarifies Transplant Test Reimbursement Limits

CareDx (CDNA) saw its stock rise by 39.4% after securing a final Medicare Local Coverage Determination. This decision clarifies reimbursement and test frequencies for its AlloSure and AlloMap transplant surveillance tests, reducing uncertainty and aligning with clinical patterns. This improved visibility impacts CareDx's investment …

Caredx Inc (CDNA) News, Articles, Events & Latest Updates

This page compiles recent news and updates for CareDx Inc. (CDNA), a precision medicine diagnostics company. Key announcements include the finalization of Medicare coverage for its transplant tests, the acquisition of Naveris to expand into oncology, and the sale of its Lab Products business. …

CareDx (CDNA) director sells 28,779 shares and exercises options

CareDx, Inc. director Hannah Valantine reported selling 28,779 shares of common stock at a weighted average price of $36.1445 per share and exercising options for the same number of shares with exercise prices ranging from $7.96 to $20.56. These transactions, which occurred on July …

[Form 4] CareDx, Inc. Insider Trading Activity

CareDx, Inc. President and CEO, Hanna John Walter JR, reported insider trading activity on July 16, 2026. He exercised 118,000 employee stock options at $8.20 per share and subsequently sold 118,000 common shares in two transactions at weighted average prices of $36.1141 and $39.0137, …

CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?

CareDx (CDNA) shares rallied 35.6% due to investor optimism following the finalization of Medicare Local Coverage Determination (LCD) for molecular testing related to solid organ allograft rejection. This policy ensures coverage for CareDx's transplant surveillance offerings in kidney, heart, and lung. While the company …

Price to earnings forward of CareDx, Inc. – GETTEX:1K9

The article focuses on the "Price to earnings forward" financial metric for CareDx, Inc. (1K9) on the Gettex exchange. It appears to be a financial data point provided by TradingView, without additional analysis or detailed financial reporting.

CAREDX INC : BTIG RAISES TARGET PRICE TO $45 FROM $28

BTIG has raised its target price for CAREDX INC (CDNA.O) to $45 from the previous $28. This update was reported by Reuters on July 17, 2026. The information presented reflects the author's opinion and is not intended as investment advice.

CareDx says final Medicare LCD maintains coverage for transplant rejection surveillance tests

CareDx announced that Medicare has finalized a Local Coverage Determination (LCD) that continues to support molecular surveillance testing for solid organ transplant rejection. The policy maintains coverage for kidney, heart, and lung offerings, establishing frequency limits for the first three years post-transplant while keeping …

Why Is CareDx Stock Skyrocketing Thursday?

CareDx (NASDAQ: CDNA) stock is skyrocketing after Medicare finalized its Local Coverage Determination (LCD) for molecular testing to monitor solid organ transplant rejection. This policy affirms continued Medicare coverage for CareDx's transplant surveillance portfolio, including testing for kidney, heart, and lung transplants. The company's …

CareDx to report Q2 2026 financial results on July 30

CareDx, Inc. announced it will release its second-quarter 2026 financial results after market close on July 30, 2026. The company will host a conference call on the same day at 4:30 p.m. ET to discuss its performance. CareDx specializes in precision medicine diagnostics for …

Caredx Inc stock hits 52-week high at 36.4 USD By Investing.com

CareDx Inc.'s stock reached a new 52-week high of $36.4, marking a 151.91% increase over the past year, driven by strong investor confidence and positive market response. Despite being potentially overvalued according to InvestingPro analysis, the company boasts "GREAT" financial health and 19% revenue …

CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

CareDx announced the finalization of the Medicare Local Coverage Determination (LCD) for molecular testing in solid organ allograft rejection, affirming coverage for its transplant surveillance offerings in kidney, heart, and lung. This policy ensures continued coverage for their AlloSure and AlloMap tests, crucial for …